OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+8.67%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$89.3M
AUM Growth
+$89.3M
(-29%)
Cap. Flow
-$45.8M
Cap. Flow
% of AUM
-51.29%
Top 10 Holdings %
Top 10 Hldgs %
48.24%
Holding
68
New
4
Increased
2
Reduced
48
Closed
7
Top Buys
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$2.43M |
| 2 |
RXDX
Ignyta, Inc.
RXDX
|
$1.77M |
| 3 |
LOXO
Loxo Oncology, Inc
LOXO
|
$1.11M |
| 4 |
Karyopharm Therapeutics
KPTI
|
$905K |
| 5 |
CKPT
Checkpoint Therapeutics
CKPT
|
$530K |
Top Sells
| 1 |
SPDR S&P Biotech ETF
XBI
|
$5.02M |
| 2 |
iShares Biotechnology ETF
IBB
|
$3.88M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$3.27M |
| 4 |
Alkermes
ALKS
|
$2.41M |
| 5 |
Incyte
INCY
|
$2.19M |
Sector Composition
| 1 | Healthcare | 78.16% |
| 2 | Real Estate | 0.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $6.97M | 6.38% | 130,500 +45,500 | +54% | +$2.43M |
|
2
Merck
MRK
$210B
| $5.36M | 4.91% | 83,700 | – | – |
|
|
3
SPDR S&P Biotech ETF
XBI
$5.07B
| $5.02M | 4.6% | 65,000 -65,000 | -50% | -$5.02M |
|
4
Bristol-Myers Squibb
BMY
$96B
| $5.02M | 4.59% | 90,000 | – | – |
|
5
AstraZeneca
AZN
$248B
| $4.09M | 3.75% | 120,000 | – | – |
|
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.92M | 3.59% | 49,095 -41,026 | -46% | -$3.27M |
|
|
7
iShares Biotechnology ETF
IBB
$5.6B
| $3.88M | 3.55% | 12,500 -12,500 | -50% | -$3.88M |
|
8
Pfizer
PFE
$141B
| $3.77M | 3.46% | 112,300 | – | – |
|
9
GSK
GSK
$79.9B
| $2.59M | 2.37% | 60,000 | – | – |
|
|
10
Alkermes
ALKS
$4.78B
| $2.47M | 2.26% | 42,623 -41,567 | -49% | -$2.41M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $2.45M | 2.24% | 18,994 -15,012 | -44% | -$1.93M |
|
|
12
Incyte
INCY
$16.5B
| $2.25M | 2.06% | 17,832 -17,408 | -49% | -$2.19M |
|
13
Ionis Pharmaceuticals
IONS
$6.79B
| $2.23M | 2.04% | 43,867 -35,033 | -44% | -$1.78M |
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $2.23M | 2.04% | 4,532 -3,503 | -44% | -$1.72M |
|
15
Mettler-Toledo International
MTD
$26.8B
| $2.12M | 1.94% | 3,594 -3,594 | -50% | -$2.12M |
|
16
Qiagen
QGEN
$10.1B
| $1.9M | 1.74% | 56,796 -54,967 | -49% | -$1.84M |
|
17
Nektar Therapeutics
NKTR
$568M
| $1.9M | 1.74% | 97,199 -89,088 | -48% | -$1.74M |
|
|
CELG
18
DELISTED
Celgene Corp
CELG
| $1.86M | 1.71% | 14,344 -13,853 | -49% | -$1.8M |
|
|
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.82M | 1.66% | 35,093 -34,419 | -50% | -$1.78M |
|
|
RXDX
20
DELISTED
Ignyta, Inc.
RXDX
| $1.77M | 1.62% | +170,500 | New | +$1.77M |
|
21
Illumina
ILMN
$15.8B
| $1.72M | 1.58% | 9,915 -9,517 | -49% | -$1.65M |
|
22
Amgen
AMGN
$155B
| $1.69M | 1.55% | 9,821 -9,580 | -49% | -$1.65M |
|
23
Biogen
BIIB
$19.4B
| $1.57M | 1.44% | 5,777 -5,627 | -49% | -$1.53M |
|
24
BioMarin Pharmaceuticals
BMRN
$11.2B
| $1.52M | 1.39% | 16,762 -16,149 | -49% | -$1.47M |
|
25
Agios Pharmaceuticals
AGIO
$2.19B
| $1.52M | 1.39% | 29,482 -27,928 | -49% | -$1.44M |
|